Legend Biotech director reports initial share holdings

Legend Biotech Corp director Ji Darren Xiaohui reported his initial ownership on a Form 3.

Accepted by SEC EDGAR 03/18/2026 - 06:55 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Legend Biotech Corp director Ji Darren Xiaohui reported his initial ownership on a Form 3. He directly holds 63,773 ordinary shares, including 34,662 restricted share units that vest in staged quarterly installments through future dates. He also holds an option immediately exercisable for 30,000 ordinary shares at an exercise price of 11.50, expiring on June 5, 2030. Each American Depositary Share represents two ordinary shares.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Ji Darren Xiaohui

Role Director

Type	Security	Shares	Price	Value
Holding	Share Option (right to buy)	--	--	--
Holding	Ordinary Shares	--	--	--

Holdings: Share Option (right to buy) — 30,000 contracts (Direct); Ordinary Shares — 63,773 shares (Direct)

Footnotes (3)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
2. F2. Includes 34,662 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 9,636 RSUs have settled, with the remainder vesting (i) as to 2,834 RSUs, in 3 equal quarterly installments beginning on March 20, 2026, (ii) as to 7,948 RSUs, in 7 equal quarterly installments beginning on March 20, 2026, and (iii) as to 14,244 RSUs, with 25% of the shares vesting on June 20, 2026 with the remainder vesting in the following 8 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
3. F3. All of the shares subject to the option are immediately exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider position did Ji Darren Xiaohui report at Legend Biotech (LEGN)?

Ji Darren Xiaohui reported an initial ownership position as a director of Legend Biotech, holding 63,773 ordinary shares directly. This total includes both settled and unvested restricted share units that will convert into ordinary shares over time, subject to continued service.

How many restricted share units does Ji Darren Xiaohui hold in LEGN?

He holds 34,662 restricted share units, each representing a contingent right to one ordinary share upon settlement. Some RSUs have already settled, while the remaining units vest in multiple equal quarterly installments starting March 20, 2026 and June 20, 2026, contingent on continued service.

What stock options does Ji Darren Xiaohui have in Legend Biotech?

He holds a share option immediately exercisable for 30,000 ordinary shares at an exercise price of 11.50, expiring on June 5, 2030. This option is a derivative security that can be converted into ordinary shares at the stated price anytime before expiration.

How are Legend Biotech ordinary shares represented by ADSs?

Legend Biotech’s ordinary shares may be represented by American Depositary Shares, or ADSs. Each ADS corresponds to two ordinary shares. This structure allows investors to trade exposure to the company’s ordinary shares on markets where ADSs are listed and traded.

Over what schedule do Ji Darren Xiaohui’s RSUs in LEGN vest?

His RSUs vest in several tranches. Certain RSUs vest in three or seven equal quarterly installments beginning March 20, 2026, while another block vests 25% on June 20, 2026, with the remainder in eight equal quarterly installments, all requiring continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ji Darren Xiaohui

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

2101 COTTONTAIL LANE

(Street)

SOMERSET NEW JERSEY 08873

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	63,773(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(3)	06/05/2030	Ordinary Shares	30,000	$11.5	D

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Includes 34,662 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 9,636 RSUs have settled, with the remainder vesting (i) as to 2,834 RSUs, in 3 equal quarterly installments beginning on March 20, 2026, (ii) as to 7,948 RSUs, in 7 equal quarterly installments beginning on March 20, 2026, and (iii) as to 14,244 RSUs, with 25% of the shares vesting on June 20, 2026 with the remainder vesting in the following 8 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

3. All of the shares subject to the option are immediately exercisable.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Pepin, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)